No Comments on „A Promising Start“

Background Discussion on MetrioPharm’s Preclinical COPD Study

Dr. Sara Schumann, Project Manager Research & Development at MetrioPharm, has led the preclinical study

MetrioPharm recently completed a study in a new preclinical model. What did this model look like?

Dr. Sara Schumann: For this initial study we chose an ex vivo model, in which the tests are performed on an isolated heart and lung system...

Read more

No Comments on MetrioPharm in the FAZ

Article from the Frankfurter Allgemeine Zeitung from December 24, 19:

© All rights reserved. Frankfurter Allgemeine Zeitung GmbH, Frankfurt.
To the newspaper article in the archive of the Frankfurter Allgemeine
Read more

No Comments on Ask the CEO – 6

Who Wants To Live Forever?

Dr. Wolfgang Brysch
CEO Dr. Wolfgang Brysch

2019 was the year of spectacular news, generated from the field of aging research. Supposedly, scientists had succeeded in slowing down the aging process, stopping it, even reversing it. As if life was an hourglass and we had learned how to stop time from running out by popping a pill, or even how to reverse the life flow.

Read more

No Comments on “A Most Extraordinary Result”

A Conversation About MetrioPharm AG’s Phase II Clinical Trial

 l.t.r.: Wolfgang Brysch, Chief Executive Officer
Barry Frankel, Senior Vice President Strategy and Business Development

MetrioPharm AG has just published Top Line Data for the Phase II clinical trial in psoriasis. Was the study a success?

Wolfgang Brysch: Yes, the study was clearly a success. We had a number of specific questions and were able to answer most of them...

Read more

No Comments on Ask the CEO – 5

How safe is MP1032? And why is that so important to us?

Dr. Wolfgang Brysch
Dr. Wolfgang Brysch

Our Phase II clinical trial in psoriasis is almost completed. And we are especially interested in one question: Has the good safety profile from our previous studies been confirmed? Nobody wants avoidable side effects. But does it really make sense that we place so much emphasis on a good safety profile in the development of MP1032? 

When I started working in medical research, m...

Read more

No Comments on Focus on InflammAging

The connection between chronic inflammation and diseases of aging

Is there a problem with increasing life expectancy? If you look at the graph of average life years alone, the development over the last fifty years looks very positive. This graph shows a steady upward trend, especially in Western countries. People are getting older continuously.

There is, however, a second graph that has risen much slower: that of healthy life expectancy...

Read more

No Comments on »MetrioPharm Is at a Pivot Point«

A Conversation with Barry Frankel, MetrioPharm’s new Senior Vice President Strategy and Business Development

Barry Frankel, MetrioPharm’s Senior Vice President Strategy and Business Development.

Do you remember first hearing about MetrioPharm?

Yes, I do remember. I have a friend, who told me to take a look at this company. I reviewed their data and the first thing I liked was the unique profile of the MP1032 platform...

Read more

No Comments on Preparations for New Studies

A report on the current projects of the MetrioPharm team

Photo: © Sandra Meissner

Timetables on the office walls, e-mails with long to-do lists and meetings of all project groups: The new year has started off busy. In order to move the MetrioPharm pipeline ahead as planned, the team is coordinating several major projects simultaneously.

One of the most important is the completion of the Phase II trial in the indication psoriasis...

Read more

No Comments on Ask the CEO – 4

The most frequently asked question in 2018: InflammAging

Dr. Wolfgang Brysch

Dr. Wolfgang Brysch

For this blog entry, we’ve been thinking: Is there a question that has been asked most frequently this year? And what does the answer say about our work at MetrioPharm?

The most frequently asked question clearly was: “Is MetrioPharm working on InflammAging?”

The so-call...

Read more